The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
OPEN Journal for immunotherapy of cancer | 27 Dec 2016
M Boyiadzis, MR Bishop, R Abonour, KC Anderson, SM Ansell, D Avigan, L Barbarotta, AJ Barrett, K Van Besien, PL Bergsagel, I Borrello, J Brody, J Brufsky, M Cairo, A Chari, A Cohen, J Cortes, SJ Forman, JW Friedberg, EJ Fuchs, SD Gore, S Jagannath, BS Kahl, J Kline, JN Kochenderfer, LW Kwak, R Levy, M de Lima, MR Litzow, A Mahindra, J Miller, NC Munshi, RZ Orlowski, JM Pagel, DL Porter, SJ Russell, K Schwartz, MA Shipp, D Siegel, RM Stone, MS Tallman, JM Timmerman, F Van Rhee, EK Waller, A Welsh, M Werner, PH Wiernik and MV Dhodapkar
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine’s clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.
* Data courtesy of Altmetric.com